Description
Application Restorase® DNA Polymerase with 10× Reaction Buffer combines Sigma′s long and accurate enzyme technology with a small amount of DNA repair enzyme. The optimized blend will initiate the repair and further amplification of damaged DNA templates greater than 800 bp. Restorase has also been shown to increase yield on undamaged DNA templates.
Features and Benefits • Reliable amplification of damaged DNA
• Increase Yield
 
Other Notes View more detailed information on Restorase DNA Polymerase at /restorase. 
  Learn more about our offering of specialty enzymes at /specialtyenzymes.
Packaging The enzyme is provided with an optimized 10× reaction buffer provided as 1 vial/250 units.
Legal Information Restorase is a registered trademark of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co.
  Use of this product is covered by one or more of the following US patents and corresponding patent claims outside the US: 5,079,352, 5,789,224, 5,618,711, 6,127,155 and claims outside the US corresponding to US Patent No. 4,889,818. The purchase of this product includes a limited, non-transferable immunity from suit under the foregoing patent claims for using only this amount of product for the purchaser’s own internal research. No right under any other patent claim （such as the patented 5′ Nuclease Process claims in US Patents Nos. 5,210,015 and 5,487,972）, no right to perform any patented method, and no right to perform commercial services of any kind, including without limitation reporting the results of purchaser’s activities for a fee or other commercial consideration, is conveyed expressly, by implication, or by estoppel. This product is for research use only. Diagnostic uses under Roche patents require a separate license from Roche. Further information on purchasing licenses may be obtained by contacting the Director of Licensing, Applied Biosystems, 850 Lincoln Centre Drive, Foster City, California 94404, USA.

Properties
concentration 2.5 units/μL
shipped in wet ice
storage temp. −20°C

Safety
Safety Statements 23-24/25